SEN and Hepatitis Virus Infections in Nontransfused Children and Pediatric Thalassemia Patients with Multiple Transfusions in Taiwan

Chiou, Shyh‐Shin; Huang, Jee‐Fu; Chang, Tai-Tsung; Hsieh, M.-H.; Dai, Chia‐Yen; Yu, Ming‐Lung; Chang, Wen‐Yu; Chuang, Wan‐Long

doi:10.1159/000100506

Cited by 3 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tattoos, medical procedures and anti-HCV-positive families have been reported to be other potential risks of HCV infection [158][159][160]. Uremic patients with maintenance hemodialysis (24 %) and beta-thalassemics (24 %) and hemophiliacs (81 %) with multiple transfusions are at high risk of HCV infection [161,162]. Recently, although the prevalence of anti-HCV seropositivity declined after the introduction of universal precaution for uremic patients [163,164], injecting drug users remain at very high risk of HCV infection in Taiwan, with a seroprevalence rate of anti-HCV [90 % [165].…”

Section: Taiwan Prevalence/risk Factorsmentioning

confidence: 99%

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

et al. 2015

Self Cite

View full text Add to dashboard Cite

Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-1.0, 14.7, 0.1-0.3, 0.9-1.9, 1.0-2.0, 5, 4.4-8.6 and 0.5-1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60-70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.

show abstract

Section: Taiwan Prevalence/risk Factorsmentioning

confidence: 99%

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Molecular prevalence and genotypes of human pegivirus-1 (HPgV-1) and SENV-like viruses among multiply transfused patients with beta-thalassemia

Bezerra

Santos

Silveira

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background/AimsTransfusion dependent subjects are at a great risk of viral hepatitis infection. We aimed to evaluate the prevalence and factors associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among transfusion-dependent patients in Taiwan.MethodsA total of 140 patients (67 thalassemic patients, 70 hemophilic patients, two patients with hereditary spherocytosis and one patient with von Willebrand disease) were prospectively enrolled to evaluate the prevalence and factors associated with viral hepatitis and spontaneous HCV clearance. All patients were tested for HBV and HCV serology and virology. Two consecutive serum samples, at least 1 year apart, were collected to clarify HCV seroclearance.ResultsThe seropositivity rate of hepatitis B surface antigen (HBsAg), HCV antibody (anti-HCV), and both HBsAg/anti-HCV were 6.4%, 45.7% and 5%, respectively. Logistic regression analysis of factors associated with anti-HCV seropositivity included age (odds ratio/95% confidence interval [OR/CI]: 1.12/1.07–1.18, P<0.001), serum alanine aminotransferase (ALT) (OR/CI: 1.04/1.02–1.06, P<0.001) and platelet counts (OR/CI: 0.995/0.991–0.998, P = 0.002). Age was the only factor independently associated with HBsAg seropositivity (OR/CI: 1.08/1.02–1.14.4, P = 0.007). Compared to patients born before 1992, the seroprevalence of HCV among thalassemic patients decreased dramatically in those born after 1992 (46.0% vs. 11.8%, p = 0.012). The seroprevalence of HCV among hemophilic patients also decreased significantly when comparing patients born before 1987 to those born after 1987 (79.5% vs. 11.5%, p<0.001). Similarly, the seroprevalence of HBV decreased significantly in the post-vaccination cohort compared to its counterpart (13.1%, vs. 1.3%, p = 0.005). The spontaneous clearance of HCV was observed in 25.4% (15/59) of patients, and ALT was the only factor associated with it (OR/CI 0.98/0.96–1.00, P = 0.02).ConclusionsBoth HBV and HCV infections are prevalent among transfusion-dependent thalassemic and hemophilic patients in Taiwan. Nevertheless, seroprevalence decreased significantly and dramatically for HCV after universal blood screening and for HBV after implementation of a universal mass vaccination program.

show abstract

SEN and Hepatitis Virus Infections in Nontransfused Children and Pediatric Thalassemia Patients with Multiple Transfusions in Taiwan

Cited by 3 publications

References 46 publications

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Molecular prevalence and genotypes of human pegivirus-1 (HPgV-1) and SENV-like viruses among multiply transfused patients with beta-thalassemia

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients

Contact Info

Product

Resources

About